Literature DB >> 23771854

Penetration of micafungin into the burn eschar in patients with severe burns.

Junichi Sasaki1, Satoshi Yamanouchi, Yukio Sato, Shinya Abe, Yotaro Shinozawa, Satoshi Kishino, Naoki Aikawa, Shingo Hori.   

Abstract

Micafungin (MCFG) concentrations in the plasma and in burn eschar were investigated after daily intravenous infusion (1 h) of MCFG (200 mg) in three patients with severe burns. MCFG treatment was initiated more than 72 h after the burn injuries. The MCFG concentrations in the plasma were determined at the end of the first administration of MCFG, immediately before the second dosing, at the end of the MCFG infusion after at least 4 days from the initial treatment, and immediately before the subsequent dosing using high-performance liquid chromatography. In addition, the trough levels in burn eschar after both the initial administration and repeated administration were measured. The peak and trough levels in the plasma were comparable to or slightly lower than the reported values in healthy volunteers. The mean (range) MCFG concentrations in the burn eschar after initial administration and repeated administration were 1.41 μg/mL (<0.1-3.98 μg/mL) and 6.65 μg/mL (1.10-14.81 μg/mL), respectively. In most cases, the MCFG concentrations in the burn eschar, especially after repeated administration, were higher than the reported MIC90 of MCFG against the clinically important pathogenic species of Candida and Aspergillus. These results suggest that MCFG is capable of penetrating burn eschar.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23771854     DOI: 10.1007/s13318-013-0146-9

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

1.  Population pharmacokinetic analysis of micafungin in Japanese patients with fungal infections.

Authors:  Kenji Tabata; Masataka Katashima; Akio Kawamura; Atsunori Kaibara; Yusuke Tanigawara
Journal:  Drug Metab Pharmacokinet       Date:  2006-08       Impact factor: 3.614

Review 2.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Candidemia and invasive candidiasis: a review of the literature for the burns surgeon.

Authors:  Jennifer F Ha; Claire M Italiano; Christopher H Heath; Sophia Shih; Suzanne Rea; Fiona M Wood
Journal:  Burns       Date:  2010-04-14       Impact factor: 2.744

4.  Candida in burns: risk factors and outcomes.

Authors:  Edwina C Moore; Alexander A Padiglione; Jason Wasiak; Eldho Paul; Heather Cleland
Journal:  J Burn Care Res       Date:  2010 Mar-Apr       Impact factor: 1.845

Review 5.  Pharmacokinetics of antibiotics in burn patients.

Authors:  M J Weinbren
Journal:  J Antimicrob Chemother       Date:  1999-09       Impact factor: 5.790

6.  Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats.

Authors:  Toshiro Niwa; Yoshiko Yokota; Akira Tokunaga; Yasuhiro Yamato; Akira Kagayama; Tomoichi Fujiwara; Junko Hatakeyama; Masaharu Anezaki; Yuko Ohtsuka; Akira Takagi
Journal:  Biol Pharm Bull       Date:  2004-07       Impact factor: 2.233

Review 7.  Micafungin.

Authors:  Blair Jarvis; David P Figgitt; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics in patients with burns.

Authors:  U Jaehde; F Sörgel
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

10.  Effect of liver and kidney function on migafungin disposition in patients with hematologic malignancies.

Authors:  Yasunori Nakagawa; Yoko Ichii; Yasuhiro Saeki; Masanobu Kodama; Satoshi Kishino; Kenshi Suzuki
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jul-Sep       Impact factor: 2.441

View more
  5 in total

1.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

3.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.

Authors:  Roeland E Wasmann; Eline W Muilwijk; David M Burger; Paul E Verweij; Catherijne A Knibbe; Roger J Brüggemann
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

5.  Penetration of echinocandins into wound secretion of critically ill patients.

Authors:  Tiziana Gasperetti; René Welte; Herbert Oberacher; Jana Marx; Ingo Lorenz; Peter Schellongowski; Thomas Staudinger; Karin Burgmann; Philipp Eller; Tobias Santner; Andrea Griesmacher; Hartwig Pfisterer; Stephan Eschertzhuber; Maria Aigner; Michael Joannidis; Romuald Bellmann
Journal:  Infection       Date:  2021-04-20       Impact factor: 3.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.